Back to Journals » Drug Design, Development and Therapy » Volume 15
Review
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date
Total article views | HTML views | PDF downloads | Totals | ||
---|---|---|---|---|---|
7,614 | Dovepress* | 6,300+ | 506 | 6,806 | |
PubMed Central* | 1,314 | 223 | 1,537 | ||
Totals | 7,614 | 729 | 8,343 | ||
*Since 14 July 2021 |
Total mentioned | Delicious | Others | |||
---|---|---|---|---|---|
6 | 0 | 0 | 0 | 3 | 3 |
View citations on PubMed Central and Google Scholar